ArticleCancer immunology, immunotherapy : CII2022

Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.

Jamila Talb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.